 Primary biliary cirrhosis PBC is a chronic cholestatic liver disease of presumed autoimmune cause characterized by progressive inflammatory destruction of interlobular and septal bile ducts, resulting in fibrosis and eventual cirrhosis 1. In PBC patients, the most disabling symptoms are fatigue and pruritus which diminish health-related quality of life HRQL. Ursodeoxycholic acid UDCA, at a dose of 13 to 15 mgkg per day, is a safe and effective medical therapy for most patients with PBC. Nevertheless, UDCA therapy has not ameliorated symptoms associated with PBC. Some UDCA-treated patients show progressive disease resulting in the liver transplantation or death from liver-related causes. For these patients, who show a persistent elevation of serum alkaline phosphatase at least twice the normal level after 6 months of UDCA monotherapy incomplete responders, the evaluation of combination therapy in clinical trials has been recommended. 